Revenue, 2025

USD 58.72 Billion

Forecast, 2035

USD 164.34 Billion

CAGR, 2026-2035

10.84%

Report Coverage

Global

Immune Checkpoint Inhibitors Market Trends for 2026

The global immune checkpoint inhibitors market size was estimated at USD 58.72 billion in 2025 and is predicted to increase from USD 65.09 billion in 2026 to approximately USD 164.34 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035. A rise in the cancer burden globally is increasing the adoption of the immune checkpoint inhibitors. Their expanding applications, innovations, approvals, and launch of new products are also enhancing the market growth.

Key Takeaways

• Immune checkpoint inhibitors market to crossed USD 65.09 billion by 2026.
• Market projected at USD 164.34 billion by 2035.
• CAGR of 10.84% expected in between 2026 to 2035.
• North America held the major revenue share of 42% in the global immune checkpoint inhibitors market in 2025.
• Asia Pacific held 22% share of the market in 2025 and is expected to grow at the fastest CAGR of 12.60% during the forecast period.
• By drug type, the PD-1 inhibitors segment held a dominant revenue share of 58% of the market in 2025 and is expected to grow at the fastest CAGR of 11.20% during the forecast period.
• By indication type, the lung cancer segment held a dominant revenue share of 34% of the market in 2025.
• By indication type, the others segment held 12% of market share in 2025 and is expected to grow at the fastest CAGR of 12.40% during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 62% in 2025.
• By end user, the cancer treatment centers segment held 28% of the market in 2025 and is expected to grow at the fastest CAGR of 11.6% during the forecast period.
• By distribution channel type, the hospital pharmacies segment held a dominant revenue share of 68% of the market in 2025.
• By distribution channel type, the online pharmacies segment held 12% of market share in 2025 and is expected to grow at the fastest CAGR of 12.10% during the forecast period.
• By therapy type, the combination therapy segment held a dominant revenue share of 54% of the market in 2025 and is expected to grow with the fastest CAGR of 12.30% during the forecast period.

What are the Immune Checkpoint Inhibitors?

The immune checkpoint inhibitors market is driven by growing cancer incidences, increasing demand for combination therapies, and expansion of treatment into earlier-stage adjuvant settings. The immune checkpoint inhibitors refer to a class of cancer immunotherapy drugs responsible for enhancing the immune system for recognition and attack cancer cells. They are used for the treatment of multiple cancer types, advanced or metastatic cancers, and long-term disease control.

Why is the Use of AI Increasing in the Immune Checkpoint Inhibitors Market?

The use of AI is increasing in the development of immune checkpoint inhibitors as they are being used for the identification of new checkpoint targets, biomarker discovery, and treatment optimization. It is also used for the analysis of tumor response, the prediction of immune-related side effects, and forecasting treatment outcomes. AI is also being used to offer personalized immunotherapy decisions and clinical trial design.

What are the Trends & Future Outlook of the Immune Checkpoint Inhibitors Market?

Blooming Combination Therapies

To enhance response rates, survival benefits, and overcome resistance, there is a rise in the development of new combination therapies. This, in turn, is driving the combinations of immune checkpoint inhibitors with chemotherapy, radiotherapy, and targeted therapies.

Emerging Next-Generation Checkpoint Targets

Growing R&D activities are driving the discovery of new immune targets such as LAG-3, TIM-3, and TIGIT. This is promoting the development of next-generation immune checkpoint inhibitors.

Expanding Clinical Applications

Increasing applications of the immune checkpoint inhibitors are driving their adoption beyond the treatment of advanced cancers. This is increasing their use for early-stage cancers and to prevent their recurrences.

Quick Facts Table

Segmental Insights

By Drug Type Insights

The PD-1 Inhibitors Segment Dominated the Market With 58% in 2025

The PD-1 inhibitors segment led the immune checkpoint inhibitors market with 58% share in 2025 and is expected to witness the fastest growth with a CAGR of 11.20% during the forecast period, due to growth in their approval rates for multiple cancers. Strong clinical efficacy is responsible for improved survival outcomes, also increasing their use. Physicians also preferred PD-1 due to better safety profiles.

The PD-L1 inhibitors segment held the second-largest share of 30% of the market in 2025, driven by the increasing use in combination regimens, which boosts their demand. Broader pipeline expansion also supports growth. Favorable reimbursement policies also improve their access.

The CTLA-4 inhibitors segment held 12% of the immune checkpoint inhibitors market share in 2025, due to their use in combination therapies. Improved dosing strategies reduce toxicity concerns, increasing their use. Growing clinical trials continue exploring new indications.

By Indication Insights

The Lung Cancer Segment Dominated the Market With 34% in 2025

The lung cancer segment accounted for the highest revenue share of 34% of the immune checkpoint inhibitors market in 2025, driven by high global incidence, which increased the demand for immunotherapy. Strong clinical outcomes in NSCLC also encouraged their adoption. Combination regimens also expanded their treatment scope.

The melanoma segment held the second-largest share of 18% of the market in 2025, due to the early success of checkpoint inhibitors sustaining usage. Their high response rates improve treatment preference. Continued innovation also enhances outcomes.

The others segment held 12% of the immune checkpoint inhibitors market share in 2025 and is expected to show the highest growth with a CAGR of 12.40% during the forecast period, driven by the expanding use of immune checkpoint inhibitors in emerging cancer types. Ongoing trials are unlocking new indications. Precision oncology also supports targeted treatment adoption.

The renal cell carcinoma segment held 12% of the market share in 2025, due to the rising use of combination therapies. Increasing diagnosis rates expand the patient pool, driving the demand for immune checkpoint inhibitors. Favorable survival benefits also drive their adoption.

By End User Insights

The Hospitals Segment Dominated the Market With 62% in 2025

The hospitals segment held a major revenue share of 62% of the immune checkpoint inhibitors market in 2025, due to the presence of advanced infrastructure that supported complex immunotherapy delivery. Higher patient inflow also increased the demand for immune checkpoint inhibitors. The availability of oncology specialists also increased their usage.

The cancer treatment centers segment held the second-largest share of 28% of the market in 2025 and is expected to expand rapidly with a CAGR of 11.6% during the forecast period, driven by their specialized oncology care, which enhances treatment outcomes. A rising number of dedicated centers also supports their growth. Increasing preference for targeted care also drives their demand.

The research institutes segment held 10% of the immune checkpoint inhibitors market share in 2025, due to growing clinical trials, which expand the use of immune checkpoint inhibitors. Academic collaborations also boost their innovation. Government funding also supports their research activities.

By Distribution Channel Insights

The Hospital Pharmacies Segment Dominated the Market With 68% in 2025

The hospital pharmacies segment held the largest revenue share of 68% of the immune checkpoint inhibitors market in 2025, driven by direct administration in hospitals, which contributed to their distribution dominance. Their specialized handling also increased their use. Additionally, the availability of oncology treatments also increased their use.

The retail pharmacies segment held the second-largest share of 20% of the market in 2025, due to increasing outpatient treatment, which is supporting the growth of retail pharmacies. Improved availability also enhances their access. Increasing specialty pharmacy services and distribution networks are also attracting patients.

The online pharmacies segment held 12% of the immune checkpoint inhibitors market share in 2025 and is expected to grow with the fastest CAGR of 12.10% during the forecast period, due to digital healthcare adoption. Enhanced convenience and accessibility also drive their usage. Expanding telemedicine platforms also supports their growth.

By Therapy Type Insights

The Combination Therapy Segment Dominated the Market With 54% in 2025

The combination therapy segment contributed the biggest revenue share of 54% of the immune checkpoint inhibitors market in 2025 and is expected to gain the highest share with a CAGR of 12.30% during the forecast period, due to their superior clinical outcomes, which promoted their rapid adoption. Synergistic effects improved response rates, increasing their demand. Ongoing trials also contributed to the expansion of the combination options.

The monotherapy segment held the second-largest share of 46% of the market in 2025, driven by its simpler treatment regimens, which drive adoption. Lower toxicity compared to combinations also supports its usage. Established efficacy also sustains their demand.

Regional Insights

Strong Regulatory Approvals Drive North America

North America dominated the immune checkpoint inhibitors market with 42% in 2025, due to strong regulatory approvals, which accelerated the adoption of immune checkpoint inhibitors. High healthcare spending also supported the use of advanced therapies. The presence of key players enhanced innovations, which contributed to the market growth.

U.S. Market Trends

High cancer prevalence across the U.S. is increasing the adoption of the immune checkpoint inhibitors. Favorable reimbursement policies are enhancing the accessibility of these products. Moreover, extensive clinical trials are also driving the development of new immune checkpoint inhibitors for a wide range of indications.

Large Patient Pool Boosts Asia Pacific

Asia Pacific held 22% share of the immune checkpoint inhibitors market in 2025 and is expected to grow at the fastest CAGR of 12.60% during the forecast period, due to a large patient pool, which drives rapid expansion of immune checkpoint inhibitors. Improving healthcare infrastructure also boosts their access. Rising investments in oncology also support their growth, enhancing the market growth.

India Market Trends

Expanding oncology infrastructure across India is driving the adoption of the immune checkpoint inhibitors. Rising health awareness is increasing the diagnosis rates and early cancer detection, ultimately increasing the demand for immune checkpoint inhibitors. Increasing affordability also drives their growth.

Immune Checkpoint Inhibitors Market Value Chain Analysis

R&D

• The R&D of the immune checkpoint inhibitors focuses on the development of next-generation combinations, subcutaneous delivery systems, and the discovery of novel targets.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Clinical Trials and Regulatory Approvals

• The safety profiles, biomarker expression, progression-free survival, and overall survival are evaluated in the clinical trials and regulatory approvals of the immune checkpoint inhibitors.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Packaging and Serialization

• The packaging and serialization of the immune checkpoint inhibitors involves the use of tamper-evident, temperature-controlled packaging and unique 2D DataMatrix barcodes.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Distribution to Hospitals, Pharmacies

• Highly specialised cold chain logistics networks and major wholesalers are responsible for the distribution of immune checkpoint inhibitors to the hospitals and pharmacies.
• Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Patient Support and Services

• Financial assistance, educational resources, and insurance navigation are provided in the patient support and services of the immune checkpoint inhibitors.
• Key players: Merck & Co., Roche, Bristol Myers Squibb.

Immune Checkpoint Inhibitors Market Top Vendors and Their Offerings

SWOT Analysis

Strengths

• The immune checkpoint inhibitors offer durable responses, which help in long-term cancer control.
• They also help in activating natural immunity, which drives their adoption rates.
• They have less cumulative toxicity and increased potential to be combined with other therapies, which increases their use.
• Their personalized treatment and enhanced effectiveness to treat multiple cancer types also increase their demand.

Weaknesses

• Limited response rates act as the major weakness in the immune checkpoint inhibitors market, reducing their adoption rates.
• Delayed onset and management complexities also limit their use.

Opportunities

• The growing cancer burden is increasing the demand for immune checkpoint inhibitors.
• A rise in the demand for personalized medicine is also increasing the development of tailored immune checkpoint inhibitors.
• The companies are also driving the development of new combination therapies to enhance the survival outcomes.
• Growing R&D activities and technological advancements are also driving their innovations.

Threats

• High manufacturing cost and production complexities limit the development of immune checkpoint inhibitors.
• Contamination and batch variability risk also reduce their innovations.

What are the Recent Developments in the Immune Checkpoint Inhibitors Market?

• In January 2026, for U.S. adults suffering from mCSCC or laCSCC and unable to receive curative radiation or curative surgery, UNLOXCYT™ (cosibelimab-ipdl) was launched by Sun Pharmaceutical Industries Limited. UNLOXCYT is a novel anti–PD-L1 antibody promoting an evolution in checkpoint inhibition, which offers a combination of proven tolerability and durable efficacy for patients with metastatic or unresectable CSCC.
• In August 2025, the launch of HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor in the Indian market, which is a globally approved treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC), was announced by Intas Pharmaceuticals. To solidify the Intas Oncology portfolio and deliver cutting-edge therapies to Indian patients, this product was launched by a strategic licensing agreement between Shanghai Henlius Biotech and Intas Pharmaceuticals.

Segments Covered in the Report

By Drug Type

• PD-1 Inhibitors
  • Nivolumab
  • Pembrolizumab
  • Cemiplimab
• PD-L1 Inhibitors
  • Atezolizumab
  • Durvalumab
  • Avelumab
• CTLA-4 Inhibitors
  • Ipilimumab
  • Tremelimumab

By Indication

• Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
• Melanoma
• Renal Cell Carcinoma
• Hodgkin Lymphoma
• Head & Neck Cancer
• Bladder Cancer
• Others
  • Gastric Cancer
  • Liver Cancer
  • Triple-negative Breast Cancer

By End User

• Hospitals
• Cancer Treatment Centers
• Research Institutes

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Therapy Type

• Monotherapy
• Combination Therapy
  • With Chemotherapy
  • With Targeted Therapy
  • Dual Immunotherapy

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA